Omeros Corporation – Product Pipeline Review – Q1 2011

Document Sample
Omeros Corporation – Product Pipeline Review – Q1 2011 Powered By Docstoc
					   Omeros Corporation – Product Pipeline Review – Q1
                         2011
                                                                                          Reference Code: GMDHC1255CDB

                                                                                                Publication Date: JUN 2011




Omeros Corporation – Product Pipeline Review – Q1 2011                                      GMDHC1255CDB / Published JUN 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Omeros Corporation – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Omeros Corporation Snapshot                                                                                           5
    Omeros Corporation Overview                                                                                       5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Omeros Corporation – Research and Development Overview                                                                6
    Key Therapeutic Areas                                                                                             6
Omeros Corporation – Pipeline Review                                                                                  9
    Pipeline Products by Stage of Development                                                                         9
    Pipeline Products – Monotherapy                                                                                  10
Omeros Corporation – Pipeline Products Glance                                                                        11
    Omeros Corporation – Late Stage Pipeline                                                                         11
         Phase III Products/Combination Treatment Modalities                                                         11
    Omeros Corporation Clinical Stage Pipeline Products                                                              12
         Phase II Products/Combination Treatment Modalities                                                          12
         Phase I Products/Combination Treatment Modalities                                                           13
    Omeros Corporation–Early Stage Pipeline Products                                                                 14
         Pre-Clinical Products/Combination Treatment Modalities                                                      14
         Discovery Products/Combination Treatment Modalities                                                         15
Omeros Corporation – Drug Profiles                                                                                   16
    OMS103HP                                                                                                         16
         Product Description                                                                                         16
         Mechanism of Action                                                                                         16
         R&D Progress                                                                                                16
    Addiction Program                                                                                                18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    OMS302                                                                                                           19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    PPAR-Gamma Agonist                                                                                               20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
    OMS201                                                                                                           22
         Product Description                                                                                         22
         Mechanism of Action                                                                                         22
         R&D Progress                                                                                                22
    Chondroprotective Program                                                                                        23
         Product Description                                                                                         23
         Mechanism of Action                                                                                         23
         R&D Progress                                                                                                23




Omeros Corporation – Product Pipeline Review – Q1 2011                                    GMDHC1255CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Omeros Corporation – Product Pipeline Review



    GPCR Program                                                                                                     24
         Product Description                                                                                         24
         Mechanism of Action                                                                                         24
         R&D Progress                                                                                                24
    GPR182                                                                                                           25
         Product Description                                                                                         25
         Mechanism of Action                                                                                         25
         R&D Progress                                                                                                25
    GPR85                                                                                                            26
         Product Description                                                                                         26
         Mechanism of Action                                                                                         26
         R&D Progress                                                                                                26
Omeros Corporation – Pipeline Analysis                                                                               27
    Omeros Corporation – Pipeline Products by Therapeutic Class                                                      27
    Omeros Corporation - Pipeline Products By Target                                                                 29
    Omeros Corporation – Pipeline Products by Route of Administration                                                30
    Omeros Corporation – Pipeline Products by Molecule Type                                                          31
Omeros Corporation – Recent Pipeline Updates                                                                         32
Omeros Corporation – Locations And Subsidiaries                                                                      35
    Head Office                                                                                                      35
    Other Locations & Subsidiaries                                                                                   35
Financial Deals Landscape                                                                                            36
    Omeros Corporation, Deals Summary, 2004 to 2011                                                                  36
    Omeros Corporation Detailed Deal Summary                                                                         37
         Venture Financing                                                                                           37
         Omeros Secures $63 Million In Series E Financing                                                            37
         Equity Offering                                                                                             39
         Omeros Completes Initial Public Offering For $68 Million                                                    39
         Affitech Enters Into Discovery and Development Agreement With Omeros                                        41
Appendix                                                                                                             42
    Methodology                                                                                                      42
         Coverage                                                                                                    42
         Secondary Research                                                                                          42
         Primary Research                                                                                            42
         Expert Panel Validation                                                                                     43
    Contact Us                                                                                                       43
    Disclaimer                                                                                                       43




Omeros Corporation – Product Pipeline Review – Q1 2011                                    GMDHC1255CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied
				
DOCUMENT INFO
Description: Omeros Corporation – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Omeros Corporation - Product Pipeline Review - Q1 2011” provides data on the Omeros Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Omeros Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Omeros Corporation and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Omeros Corporation - Brief Omeros Corporation overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Omeros Corporation human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Omeros Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Omeros Corporation’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Omeros Corporation’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Omeros Corporation in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Omeros Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensin
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries